PAYX has posted its fiscal Q4 results and bounced 2.1% on Tuesday to $97.99 — but the week's net move is still negative 2.3%, and options traders shifted more defensive into the print than at any point in recent months.
The options signal is the most striking data point in the post-earnings snapshot. The put/call ratio climbed to 0.74 on Tuesday — more than 3.4 standard deviations above its 20-day average of 0.61. That's the highest z-score reading in the trailing data, and it lands the day of results rather than receding after them, suggesting the hedging demand didn't fully unwind on the bounce. The 52-week range for the PCR runs from 0.41 to 1.71, so the absolute level isn't extreme — but the deviation from recent norms is notable for a name that spent most of May and early June trading with a near-zero z-score.
The borrow market tells a calmer story, and it's worth naming the contrast explicitly. Availability has tightened from around 830% two weeks ago to 641% now — a meaningful move in percentage terms, but still firmly in loose territory. There are roughly six shares available to lend for every one already borrowed. Cost to borrow has drifted up roughly 23% over the past month to 0.52%, but remains low in absolute terms. Short interest itself has nudged higher — 5.7% of the free float, up about 1.3% on the week — reversing the pre-earnings retreat noted in prior notes. The direction has shifted back toward modest rebuilding, but nothing in the lending market suggests a squeeze or structural tightening.
The analyst picture remains split. The most consequential recent move belongs to Citi, which upgraded PAYX to Buy on June 15 and lifted its target from $99 to $140 — a call that was already live before the earnings print and hasn't been revised since. Stifel raised its Hold target modestly to $110. The consensus mean sits at $105.43, implying about 7.6% upside from Tuesday's close. That gap looks more interesting now that the stock has pulled back on the week, but it masks a genuine disagreement: JPMorgan carries an Underweight with a $100 target, Wells Fargo is also Underweight at $95, and Baird's neutral call puts fair value at $125. The EPS momentum factor score of 97 — among the highest in the universe — and a dividend score of 98 suggest the fundamental picture looks solid to quant screens, even if organic growth guidance remains a sticking point for bears.
Capital Research added a significant 3.6 million shares in its last reported filing, making it the second-largest institutional holder at 9.2% of shares. BlackRock added half a million shares in the same period. Founder B. Golisano trimmed 274,000 shares but retains a 9.96% stake. Insider activity in the trailing 90 days is net positive by a thin $378,000 — small in dollar terms and not a meaningful directional signal, though the pattern of SVP-level sales at $90 earlier in the year did occur when the stock was 8% lower than current levels.
Peers pulled in different directions on the week: ADP fell 1.2% and PCTY dropped 5.6%, while PAYC lost 7.7%. PAYX's 2.3% weekly decline looks relatively contained against that peer group, though the sector-wide pressure complicates any read on stock-specific sentiment.
The next meaningful data point to watch is whether the post-earnings options skew normalises back toward the 20-day average — or whether the elevated put/call ratio persists, which would indicate the market remains unconvinced by the Q4 result.
See the live data behind this article on ORTEX.
Open PAYX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
